N@N

Trius Therapeutics Inc (NASDAQ:TSRX), Up By 11.76% ($0.65) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, March 5t

^{Published on 2013-03-06 07:46:46 - WOPRAI}
 

March 6, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Tuesday, March 5th 2013 at 07:16:00 PST stating that Trius Therapeutics Inc (NASDAQ:TSRX) was expected to be Up After it crossed above its SqueezeTrigger Price of 5.49 on Tuesday, March 5th 2013. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=tsrx&id=352187

From August 2009 to February 2013, an aggregate amount of 20691027 shares of TSRX have been shorted for a total dollar value of $103455135. The TSRX SqueezeTrigger price of $5.49 is the volume weighted average price that all shorts are short in shares of TSRX. There is still approximately $5,696,880 of potential short covering in shares of TSRX.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

Trius Therapeutics Inc (NASDAQ:TSRX) - Trius Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibiotics for life-threatening infections. The company s lead investigational drug, tedizolid phosphate, is a once daily, IV, and orally administered second generation oxazolidinone that completed Phase III clinical development for the treatment of acute bacterial skin and skin structure infections. It also has two preclinical programs to identify and develop antibiotics to treat infections caused by gram-negative and gram positive bacteria; and the marine natural products preclinical program to identify and develop antibiotics for use as countermeasures for biodefense threats. Trius Therapeutics has a license agreement with Dong-A Pharmaceutical Co., Ltd. to develop and commercialize licensed products, including tedizolid phosphate, outside of Korea; a cooperative research and development agreement with Lawrence Livermore National Security LLC for researching and developing gram-negative biodefense pathogens; a research agreement with UCSD for jointly researching antibacterial agents for combating gram-negative and gram-positive biodefense pathogens; a research contract with Lawrence Livermore National Laboratory for the development of antibiotics directed against gram negative multi-drug resistant bacterial pathogens; and a collaboration and license agreement with Bayer to develop and commercialize tedizolid phosphate in the Bayer licensed territory. The company was formerly known as Rx3 Pharmaceuticals, Inc. and changed its name to Trius Therapeutics, Inc. in February 2007. Trius Therapeutics, Inc. was incorporated in 2004 and is headquartered in San Diego, California..

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net